Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
DOSAGE study: protocol for a phase III non-inferiority randomised trial investigating dose-reduced chemotherapy for advanced colorectal cancer in older patients.
Baltussen JC, van den Bos F, Slingerland M, Binda TRR, Liefers GJ, van den Hout WB, Fiocco M, Verschoor AJ, Cloos-van Balen M, Holterhues C, Houtsma D, Jochems A, Spierings LEAMM, van Bodegom-Vos L, Mooijaart SP, Gelderblom H, Speetjens FM, de Glas NA, Portielje JEA. Baltussen JC, et al. Among authors: speetjens fm. BMJ Open. 2024 Aug 13;14(8):e089882. doi: 10.1136/bmjopen-2024-089882. BMJ Open. 2024. PMID: 39142680 Free PMC article.
Time trends in treatment patterns and survival of older patients with synchronous metastatic colorectal cancer in the Netherlands: A population-based study.
Baltussen JC, de Glas NA, Liefers GJ, Slingerland M, Speetjens FM, van den Bos F, Cloos-van Balen M, Verschoor AJ, Jochems A, Spierings LEAMM, Holterhues C, van Gerven LA, Mooijaart SP, Portielje JEA, Derks MGM. Baltussen JC, et al. Among authors: speetjens fm. Int J Cancer. 2023 May 15;152(10):2043-2051. doi: 10.1002/ijc.34422. Epub 2023 Jan 13. Int J Cancer. 2023. PMID: 36620951
Phase I/II study protocol to assess safety and efficacy of adoptive cell therapy with anti-PD-1 plus low-dose pegylated-interferon-alpha in patients with metastatic melanoma refractory to standard of care treatments: the ACTME trial.
van der Kooij MK, Verdegaal EME, Visser M, de Bruin L, van der Minne CE, Meij PM, Roozen ICFM, Jonker MA, van den Bosch S, Liefers GJ, Speetjens FM, van der Burg SH, Kapiteijn E. van der Kooij MK, et al. Among authors: speetjens fm. BMJ Open. 2020 Nov 24;10(11):e044036. doi: 10.1136/bmjopen-2020-044036. BMJ Open. 2020. PMID: 33234662 Free PMC article.
Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: a phase I/II clinical trial.
Zeestraten EC, Speetjens FM, Welters MJ, Saadatmand S, Stynenbosch LF, Jongen R, Kapiteijn E, Gelderblom H, Nijman HW, Valentijn AR, Oostendorp J, Fathers LM, Drijfhout JW, van de Velde CJ, Kuppen PJ, van der Burg SH, Melief CJ. Zeestraten EC, et al. Among authors: speetjens fm. Int J Cancer. 2013 Apr 1;132(7):1581-91. doi: 10.1002/ijc.27819. Epub 2012 Nov 21. Int J Cancer. 2013. PMID: 22948952 Clinical Trial.
Risk of venous thromboembolism and major bleeding in the clinical course of osteosarcoma and Ewing sarcoma.
Kaptein FHJ, Stals MAM, Evenhuis RE, Gelderblom H, Huisman MV, Karis DSA, Noten RWD, Cannegieter SC, Speetjens FM, Verschoor AJ, Versteeg HH, van de Sande MAJ, Klok FA. Kaptein FHJ, et al. Among authors: speetjens fm. Thromb Res. 2023 Jan;221:19-25. doi: 10.1016/j.thromres.2022.11.007. Epub 2022 Nov 18. Thromb Res. 2023. PMID: 36435048 Free article.
Survival Analysis of 3 Different Age Groups and Prognostic Factors among 402 Patients with Skeletal High-Grade Osteosarcoma. Real World Data from a Single Tertiary Sarcoma Center.
Evenhuis RE, Acem I, Rueten-Budde AJ, Karis DSA, Fiocco M, Dorleijn DMJ, Speetjens FM, Anninga J, Gelderblom H, van de Sande MAJ. Evenhuis RE, et al. Among authors: speetjens fm. Cancers (Basel). 2021 Jan 27;13(3):486. doi: 10.3390/cancers13030486. Cancers (Basel). 2021. PMID: 33513855 Free PMC article.
Relative Wash-In Rate in Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a New Prognostic Biomarker for Event-Free Survival in 82 Patients with Osteosarcoma: A Multicenter Study.
Kalisvaart GM, Evenhuis RE, Grootjans W, Van Den Berghe T, Callens M, Bovée JVMG, Creytens D, Gelderblom H, Speetjens FM, Lapeire L, Sys G, Fiocco M, Verstraete KL, van de Sande MAJ, Bloem JL. Kalisvaart GM, et al. Among authors: speetjens fm. Cancers (Basel). 2024 May 21;16(11):1954. doi: 10.3390/cancers16111954. Cancers (Basel). 2024. PMID: 38893075 Free PMC article.
47 results